Antibody response to escherichia coli L-asparaginase: Prognostic significance and clinical utility of antibody measurement

American Journal of Pediatric Hematology/Oncology

Volumn 8, Issue 2, 1986, Pages 99-104

  Cheung, Nai Kong V ^a   Chau, Irene Y ^a   Coccia, Peter F ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G4;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANAPHYLAXIS; ANTIBODY RESPONSE; BLOOD AND HEMOPOIETIC SYSTEM; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; ESCHERICHIA COLI; HUMAN; PROGNOSIS; THERAPY;

ADOLESCENT; ANTIBODY FORMATION; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; ESCHERICHIA COLI; FEMALE; FOLLOW-UP STUDIES; HUMAN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INFANT; KINETICS; LEUKEMIA, LYMPHOCYTIC; LYMPHOMA; MALE; PROGNOSIS; RADIOIMMUNOASSAY;

EID: 0022982465     PISSN: 01928562     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Capizzi RL, Berlino JR, Skeel RT, et al. L-Asparaginase: clinical, biochemical, pharmacological, and immunological studies. Ann Intern Med 1971;74:893-901.
2. Ortega JA, Nesbit ME, Donaldson MH, et al. L-Asparaginase, vincristine, and prednisone for induction of first remission in acute lymphocytic leukemia. Cancer Res 1977;37:535-540.
3. Coccia PF, Bleyer WA, Siegel SK, et al. Development and preliminary findings of children’s cancer study group protocols (161, 162 and 163) for low-, average- and high-risk acute lymphoblastic leukemia in children. In: Murphy SB, Gilbert JR, eds. Leukemia research.(Advances in cell biology and treatment). New York: Elsevier Science Publishing Co., 1983;241-250.
4. Capizzi RL. Schedule-dependent potentiation of the activity of methotrexate and high-dose ara-C by asparaginase in treatment of the acute leukemias. In: Murphy SB. Gilbert JR, eds. Leukemia Research.(Advances in cell biology and treatment). New York: Elsevier Science Publishing Co., 1983;146-155.
5. Wilbur JR, King OY. Repeated use ofL-asparaginase in the treatment of children with acute leukemia in relapse [Abstract]. In: Proceedings of the American Society of Clinical Oncology. 1983;C-279.
6. Clavell L, Hitchcock-Bryan S, Gelber R, et al.: 5-Year experience with high-dose asparaginase (HDA) in childhood acute lymphoblastic leukemia (ALL). Blood 1982;60(suppl):153a.
7. Evans WE, Tsiatis A, Rivera G, et al. Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma. Cancer 1982;49:1378-1383.
8. Dellinger CT, Miale TD. Comparison of anaphylactic reactions to asparaginase derived from Escherichia coli and from Erwinia cultures. Cancer 1976;38:1843-1846.
9. Obnuma T, Holland JE, Meyer P. Erwinia carotovora asparaginase in patients with prior anaphylaxis to asparaginase from E. coli. Cancer 1972;30:376-381.
10. Nesbit M, Chard R, Evans A, et al. Evaluation of intramuscular versus intravenous administration ofL-asparaginase in childhood leukemia. Am J Hemalol Oncol 1979;1:9-13.
11. Albo V, Miller D, Leiken S, et al. Toxicity experience with a 2nd course of E. coliL-asparaginase (L-ASP) therapy 3 years after induction course in children with acute lymphoblastic leukemia (ALL) in continuous remission [Abstract]. In: Proceedings of the American Socials of Clinical Oncology. 1983;C-263.
12. Killander D, Dohlwitz A, Engstedt L, et al. Hypersensitivereactions and antibody formation durinyL-asparaginase treatment of children and adults with acute leukemia. Cancer 1976;37:220-228.
13. Peterson RG, Handschumachcr RE, Mitchell MS. Immunological responses toL-asparaginase. J Clin Invest 1971;50:1080-1090.
14. Weetman RM, Coates TD, Griep JA. Asparaginase induced immune hemolytic anemia [Abstract]. In: Proceedings of the American Society of Clinical Oncology. 1982;C-101.
15. Lowry J, Rosehrough NJ, Farr AL, et al. Protein measurement with folin phenol reagent. J Biol Chem 1951;193:265-270.
16. Cheung N-KV, Blessing-Moore J, Reid MJ, et al. Reduction of interference by specific IgG with a modified microtiter solid phase radioimmunoassay to measure honeybee venom IgE. J Allergy Clin Immunol 1983;71:283-293.
17. Cheung N-KV, Blessing-Moore J, Reid MJ, et al. Honeybee venom specific immunoglobulin G4 in honeybee sting allergic patients and beekeepers. Ann Allergy 1983;50:155-160.
18. Steuber CP, Levy GJ, Nix WL, et al. Use ofL-asparaginase and cytosine arabinoside for refractory acute lymphocytic leukemia with particular reference to T-cell leukemia. Med Pediatr Oncol 1978;5:33-38.
19. Goodwin BFT. Nonreaginic anaphylactic antibodies in man. Clin Rev Allerg 1983;1:249-255.
20. Aalherse RC, Dieges PH, Knul-Bretlova V, et al. IgG4as a blocking antibody. Clin Rev Allerg 1983;1:289-295.
21. Humphrey GB, Lankford J, Oleinick S, et al. Leukemic serum inhibition of phytohemagglutinin-induced transformation. J Immunol 1974;113:63-69.
22. Leikin S, Miller D, Sather H, et al. Immunologic evaluation in the prognosis of acute lymphoblastic leukemia. A report from Children’s Cancer Study Group. Blood 1981;58:501-507.
23. Schucpback J, Sauter C. Inverse correlation of antiviral antibody tilers and the remission length in patients treated with viral oneolysate: a possible new prognostic sign in acute myelogenous leukemia. Cancer 1981;48:1363-1367.
24. Hellstrom KE, Hellstrom I. Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens. In: Dixon FJ, Kunkel HG, eds. Advances in Immunology, vol. 18. New York: Academic Press. 1974;209-232.